Oregon Public Employees Retirement Fund Invests $290,000 in Diplomat Pharmacy Inc (DPLO) Stock

Share on StockTwits

Oregon Public Employees Retirement Fund acquired a new stake in Diplomat Pharmacy Inc (NYSE:DPLO) in the fourth quarter, HoldingsChannel reports. The fund acquired 21,525 shares of the company’s stock, valued at approximately $290,000.

A number of other hedge funds have also added to or reduced their stakes in DPLO. BlackRock Inc. lifted its position in shares of Diplomat Pharmacy by 17.0% during the 3rd quarter. BlackRock Inc. now owns 8,464,251 shares of the company’s stock worth $164,292,000 after purchasing an additional 1,228,490 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Diplomat Pharmacy by 9.4% during the 3rd quarter. Janus Henderson Group PLC now owns 5,892,046 shares of the company’s stock worth $114,365,000 after purchasing an additional 506,878 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Diplomat Pharmacy by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,461,715 shares of the company’s stock worth $106,011,000 after purchasing an additional 209,939 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Diplomat Pharmacy by 4.0% during the 3rd quarter. Vanguard Group Inc now owns 5,461,715 shares of the company’s stock worth $106,011,000 after purchasing an additional 209,939 shares during the last quarter. Finally, Capital International Investors purchased a new stake in shares of Diplomat Pharmacy during the 3rd quarter worth $99,092,000. Institutional investors own 86.58% of the company’s stock.

Several research firms have recently issued reports on DPLO. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 27th. Leerink Swann lowered shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating and set a $30.00 price target on the stock. in a research note on Monday, February 25th. JPMorgan Chase & Co. lowered shares of Diplomat Pharmacy from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $8.00 in a research note on Friday, February 22nd. Barclays reiterated an “overweight” rating and set a $8.00 price target (down from $18.00) on shares of Diplomat Pharmacy in a research note on Monday, February 25th. Finally, Lake Street Capital lowered shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and cut their price target for the stock from $30.00 to $15.00 in a research note on Tuesday, January 8th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $13.78.

NYSE DPLO opened at $6.42 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $485.54 million, a price-to-earnings ratio of 7.64 and a beta of 0.74. Diplomat Pharmacy Inc has a one year low of $5.56 and a one year high of $28.74.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/4223287/oregon-public-employees-retirement-fund-invests-290000-in-diplomat-pharmacy-inc-dplo-stock.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nordson  Posts  Earnings Results, Misses Expectations By $0.06 EPS
Nordson Posts Earnings Results, Misses Expectations By $0.06 EPS
LGL Group Inc  CEO Michael J. Ferrantino Sells 10,100 Shares
LGL Group Inc CEO Michael J. Ferrantino Sells 10,100 Shares
Snap Inc  CAO Sells $11,998.47 in Stock
Snap Inc CAO Sells $11,998.47 in Stock
Evolus  PT Set at $31.00 by Mizuho
Evolus PT Set at $31.00 by Mizuho
Unification  Price Hits $0.0362 on Exchanges
Unification Price Hits $0.0362 on Exchanges
DaTa eXchange  Trading Up 11% This Week
DaTa eXchange Trading Up 11% This Week


© 2006-2019 Ticker Report